
Motsoaledi's big HIV treatment jump: Is it true?
Last month, the health minister said that more than half a million previously diagnosed people with HIV have been started on treatment since the end of February.
But can it really be, especially since the gap to getting 95% of people diagnosed with HIV on medication has been hovering around 1-million for the past five years?
Critics say they're sceptical about the minister's figures — and that the country will close the gap by December.
Numbers are powerful.
They can also be dangerous — if not used correctly.
When the health minister said last month that 520 700 extra people previously diagnosed with HIV had been started on treatment since the end of February, the number sounded astounding.
The health department's goal is to find 1.1-million people who know they have HIV, but either never started treatment, or fell out of treatment, before the end of the year.
In his words, the department has reached 'more than 50% of the target' they set out to achieve by the end of the year.
If that gap is closed, South Africa would have met two of the three so-called 95-95-95 goals the country signed up for as part of the United Nations plan to end Aids as a public health threat by 2030.
However, knowing by exactly how much the gap is closing is tricky, because people who know they have HIV may start and stop and then restart treatment again later — sometimes several times — during the course of their care.
In fact, a study from the Western Cape shows that close to half of people on medication stop at least once, and that some even pause and then restart up to three times.
So, many of the 520 700 previously diagnosed people Motsoaledi says are now on medication could, at least in theory, very well be people who are counted repeatedly as they cycle in and out of treatment. But because the patient information system isn't digitally centralised — most clinics still keep track of their clients on paper, which means different facilities can't easily access one another's records — someone who stops treatment at one clinic can easily be counted as a new start at another, rather than a restart.
The set of UN targets aim for 95% of people in a country with HIV to know their diagnosis, 95% of those to be on treatment and 95% of those taking medication to have such low levels of virus in their bodies that they can't infect someone through sex.
'The reason that we [were] able to reach half a million within a short space of time, was because of weekly check-in meetings with provinces, where reports that come from the ground are verified in the presence of all provincial colleagues before they are regarded as final figures for reporting,' said the minister.
But simply counting better isn't the same as doing better, and critics called the reported progress 'inconceivable'.
Why?
Because for the last few years, the number of people with HIV who have gone on treatment has crept up very slowly, so much so that the gap to 95% has remained more or less the same for about five years. (At the moment just over 80% of people diagnosed with HIV are on treatment.)*
Moreover, that was while treatment programmes had funding and US-backed money for HIV projects was in place.
So now, at a time of funding shortfalls, programmes closing and the government scrambling to plug the holes, could nearly half of the number of people who need to get on treatment really have been added in just 10 weeks?
We dive into the data to get a sense of what the numbers really mean.
Mind the gap
In 2021, South Africa was about 1.2 million people short of its 95%-treatment goal; by 2025 the shortfall will likely be 990 000. That means that the gap — that is, the difference between where the country actually is and where it wants to be when it comes to HIV treatment — has closed by about 210 000.
Bhekisisa
So, there's been progress, but it's been slow: in total, only about 700 000 more people are on HIV medication today than five years ago.
'Getting that last one million or so people on treatment is not simple,' says Kate Rees, public health specialist at the Anova Health Institute. Part of the reason for this, she says, is that a large proportion of the group needed to close the gap are people who have in fact been on ARVs before but have since stopped.
Sometimes people miss an appointment to get a refill of their medicine because they can't afford to take time off work to go to the clinic or they might have moved to another province or district and so they don't go back to the facility where they first got their prescription, she explains. The longer the interruption lasts, the more hesitant people are to go back, says Rees, because they dread being treated poorly or getting 'kicked to the back of the queue' for having missed an appointment, with especially people like sex workers, trans folk or men who have sex with men facing judgement.
Says Rees: 'The health service expects people to be very rigid with their appointments, but life just is not like that.'
Slow progress
To get a sense of the progress towards meeting the UN's second target in its 95-95-95 cascade, it's best to look at the difference in the total number of people on HIV treatment from year to year, says Leigh Johnson, one of the lead developers of the Thembisa model, which is used to report South Africa's official statistics to UNAids.
Bhekisisa
Although the number of people on medication is increasing, the number grows less and less each year. For example, in 2020, about 291 000 more people were on treatment than in 2019. By 2021, though, the number had grown only by about 225 000.
Current forecasts from the model are that the total number of people on treatment will grow by only around 160 000 this year. But that's based on programmes running like they have up to now — and with recent upsets because of US funding cuts, it may be an unreasonable assumption, Johnson says.
Part of the reason for the small net gain every year, is that although many people sign up for medication in a year, many also stop coming back to get their scripts refilled. Of those who drop out of treatment, some might choose to restart within a couple of months again, while others may pause their treatment for more than a year.
Bhekisisa
In 2023, for example, roughly 793 500 people who had been on treatment before weren't any longer, but about 728 000 who received medication were restarters, Thembisa numbers show.
Bhekisisa
So even though some people who stop taking their medication might not restart — or restart quickly — the total number who are on treatment still grows; it's just slow-going. This means getting a handle on how close to — or far from — the 95%-treatment mark South Africa is, is more dynamic than simple addition.
Stops, starts and restarts
'There will always be people who interrupt their treatment,' says Rees. 'It's not possible to keep everyone perfectly in the system all the time — that's life.'
But what's important, she says, is to make those pauses as short as possible by helping people to get back on medication quickly and easily — without judgement.
Gesine Meyer-Rath agrees. She's a health economist at HE2RO, a health economics research group at the University of the Witwatersrand, and focuses on how the government can get the most bang for its buck in its HIV programme.
Data in the Thembisa model shows that over the years, the number of people starting medication for the first time — in other words, those who have never been on treatment before — has shrunk, but at the same time counts of restarters have grown. Her group's analyses have shown that honing in on keeping people on HIV treatment is the best way to go — especially now that funding is shrinking — and that 'we can close the 1.1-million gap through improved retention alone'.
But to plan sensibly, she explains, policymakers should know how many people are first-time starters, how many pause treatment but then restart, and how many stop and don't come back at all.
'The more detail programme planners have in the data, the better,' she says. 'The [government's] 'Close the Gap' campaign has a lot of good ideas, but having the right numbers of where the gap is that we want to close is crucial, as is keeping these numbers accurate as we progress.'
This is exactly where things can become tricky in future if the holes left by the US funding cuts aren't plugged.
Because of the US's aid withdrawal, about 40% of South Africa's HIV data capturers will likely have lost their jobs by September, Bhekisisa reported last month, and this means the information needed to shape where money has to be spent to make real progress in ending Aids as a public health threat over the next five years simply might not be available.
Says Meyer-Rath: 'The less data we have, the more we're flying blind, which leaves space for bickering over the data that is still there.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
23 minutes ago
- Associated Press
Thrive Health Systems Announces Patient Transformation from Cane to Handstands
Thrive Health Systems announces a patient's remarkable journey from relying on a cane to performing handstands through personalized healthcare. Colorado Springs, Colorado, USA, August 16, 2025 -- Thrive Health Systems Transforms Patient Life with Comprehensive Care Approach Thrive Health Systems, is revolutionizing the healthcare experience with its holistic, multi-disciplinary approach. The clinic's latest success story highlights how targeted treatments and personalized care can not only alleviate chronic pain but also restore an individual's quality of life. A recent patient, who once relied on a cane for mobility, achieved an inspiring transformation and is now performing handstands, showcasing the life-changing results Thrive Health Systems offers. Thrive Health Systems employs a multi-faceted treatment model that combines chiropractic care, functional medicine, massage therapy, nutrition, and movement training. The clinic's approach focuses on treating the root causes of health conditions rather than simply masking symptoms, ensuring long-term wellness and vitality. Patient Journey from Cane to Handstands One of the most remarkable success stories at Thrive Health Systems is that of a patient who had become dependent on a cane due to chronic pain and limited mobility. After a tailored treatment plan crafted by Dr. Kallenbach and the Thrive team, this patient experienced profound improvements in their health. Through a combination of spinal decompression, Class IV laser therapy, and individualized rehab programs, the patient's pain diminished, and their mobility increased. Incorporating functional movement training, nutritional counseling, and holistic therapies helped the patient regain strength and flexibility, eventually allowing them to go beyond simple mobility and engage in physical feats like performing handstands. This patient's journey from needing a cane to achieving this level of activity exemplifies the transformative power of Thrive Health Systems' patient-centered approach. The Thrive Health Systems Approach to Root Cause Healthcare Thrive Health Systems stands out from traditional healthcare providers by offering a comprehensive, root-cause approach to patient care. Dr. Kallenbach and her team emphasize the importance of understanding the deeper causes behind health conditions. Rather than just treating symptoms, Thrive Health Systems works to uncover the underlying issues, ensuring patients not only recover but thrive. The clinic's services include spinal decompression therapy, shockwave therapy for tissue healing, functional movement training, and personalized rehab programs. Additionally, Thrive Health Systems' functional medicine approach addresses chronic conditions such as thyroid dysfunction, autoimmune disease, digestive issues, fatigue, and hormonal imbalances using advanced diagnostics and personalized treatment plans. The Thrive Health Systems Difference Thrive Health Systems is dedicated to providing natural, holistic healthcare that delivers real results. The clinic's broad range of services allows it to treat patients dealing with multiple health issues all in one place. Thrive Health Systems' team of experts, including chiropractors, functional medicine practitioners, massage therapists, and nutritionists, work collaboratively to design personalized plans that support long-term health and wellness. The clinic's success stories, like that of the patient who went from a cane to handstands, reflect the effectiveness of this comprehensive care model. Patients at Thrive Health Systems don't just find relief; they regain the strength and vitality necessary to live an active, healthy life. Commitment to Sustainable Health and Wellness As Thrive Health Systems continues to expand across Colorado, Dr. Kallenbach remains committed to delivering high-quality, individualized care. The clinic's patient-focused approach, which integrates cutting-edge technology and compassionate care, ensures that each person receives the tools and support needed to achieve optimal health. With locations in Colorado Springs, Arvada, and Centennial, Thrive Health Systems is dedicated to helping individuals lead healthier, more vibrant lives. The clinic's combination of chiropractic care, functional medicine, and wellness services is setting a new standard for comprehensive healthcare in Colorado and beyond. About Thrive Health Systems: Founded in 2009 in Colorado Springs , Thrive Health Systems is committed to providing multi-disciplinary, natural healthcare solutions. With locations in Colorado Springs, Arvada, and Centennial, Thrive Health Systems combines chiropractic care, functional medicine, massage therapy, and more to address the root causes of pain and illness. The clinic's holistic approach helps patients recover and thrive, empowering them to live healthier, more vibrant lives. Media Contact: Joshua Fuson Thrive Health Systems Email: [email protected] Website: Thrive Health Systems Instagram: @thrivehealthsystems Facebook: Thrive Health Systems LinkedIn: Thrive Health Systems YouTube: Thrive Health Systems Channel Contact Info: Name: Joshua Fuson Email: Send Email Organization: Thrive Health Systems Website: Release ID: 89167434 If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
Yahoo
an hour ago
- Yahoo
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
Novo Nordisk A/S (NYSE:NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Underperform with a $54 price target. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors that it sees a more balanced risk/reward now that the company's 'reality' is better reflected in the shares. Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Jim Cramer on UnitedHealth: 'It Could Come Back'
UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks Jim Cramer shed light on. Cramer showed a slight bit of optimism toward the company as he said: 'I think UnitedHealth's going to work here… I think it's going to work. I really do. Look, I'm not a believer. I don't like the fact that they had shenanigans, but I will say this: I think that the company is run by a very good CEO. It could come back.' Ken Wolter/ UnitedHealth Group Incorporated (NYSE:UNH) provides health benefits, pharmacy care, care delivery, and health management services. In addition, the company offers data analytics and technology-driven solutions for individuals, employers, governments, and health systems. During the August 7 episode, when a caller inquired about the company stock, Cramer responded: 'I have long known, this is something I learned probably in my second decade of trading or investing: You do not buy or sell something where you have no idea what is really happening. And at UnitedHealth, there isn't anyone other than the CEO and probably 52,000 lawyers who has any idea what's going on.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos